newsfilter
← Latest News
GlobeNewswire·

Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study

Patient from the Company’s completed Phase II study remains cancer-free and in good health at the ten-year survival milestone Ramat Gan, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF)